← European Medicine Shortage Tracker · all medicines
Availability information only — Mobi Doctor doesn't sell medicines; check with a pharmacy.
Doxorubicin hydrochloride currently has availability issues reported in 4 European registers: Germany, Spain, Ireland, Sweden.
Shortage ATC L01DB01 · also listed as: Doxorubicinhydrochlorid · DOXORUBICINA · DOXORUBICIN HYDROCHLORIDE · doxorubicinhydroklorid · data refreshed 12 September 2026
As of 12 September 2026, 4 of the 9 tracked registers list current availability issues for Doxorubicin hydrochloride, covering 8 affected product presentations. The longest-running open report was filed in Germany on 2024-08-16 and has now been open for about 25 months. Where agencies state a cause, manufacturing problems lead with 4 of the 4 stated-cause reports. The furthest expected-resolution date currently on file is 2027-01-19; the earliest is 2026-09-30. Notably, 1 report has already passed the expected-resolution date without closing — prognoses for this medicine should be read as estimates, not commitments. The issue spread across registers over time rather than at once: Germany reported first (2024-08-16), with Spain following roughly 16 months later — a pattern typical of supply problems cascading between national markets. Registers in Germany, Spain, Ireland, Sweden indicate that alternatives or equivalents are available — a pharmacist or doctor can advise on switching. In the WHO ATC classification, Doxorubicin hydrochloride is coded L01DB01 — a medicine acting on antineoplastic and immunomodulating agents — so clinically related products appear under “Related medicines” below.
| Where | Status & products | Since | Expected end | Reason / alternatives | Source |
|---|---|---|---|---|---|
| 🇩🇪 Germany | Shortage DOXO-cell 150 mg Injektionslösung + 2 more productsDOXO-cell 50 mg Injektionslösung Doxorubicinhydrochlorid Bendalis 2 mg/ml | 2024-08-16 | 2027-01-19 | Probleme in der Herstellung Alternatives: N/A | register ↗ |
| 🇪🇸 Spain | Shortage DOXORUBICINA ACCORD 2 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION EFG, 1 via de 50 ml | 2025-12-17 | 2026-10-29 | Existen otros medicamentos con el mismo principio activo y misma vía. Alternatives: Existe/n otro/s medicamento/s con el mismo principio activo y para la misma vía de administración. | register ↗ |
| 🇮🇪 Ireland | Shortage Doxorubicin Teva 2 mg / ml Concentrate for Solution for Infusion | 2024-11-05 | — | Manufacturing delay Alternatives: Alternative(s) available — see the national register. | register ↗ |
| 🇸🇪 Sweden | Shortage Doxorubicin Teva 2 mg/ml Injektionsvätska, lösning + 2 more productsZolsketil pegylated liposomal 2 mg/ml Koncentrat till infusionsvätska, dispersio Zolsketil pegylated liposomal 2 mg/ml Koncentrat till infusionsvätska, dispersio | 2025-01-01 | 2026-12-31 | — Alternatives: Alternative(s) available — see the national register. | register ↗ |
Every individual register entry for Doxorubicin hydrochloride in the tracked sources, newest first — including resolved and discontinued reports.
| Reg. | Product | Status | Reported | Expected end | Stated reason |
|---|---|---|---|---|---|
| 🇸🇪 SE | Zolsketil pegylated liposomal 2 mg/ml Koncentrat till infusionsvätska, | Shortage | 2026-02-06 | 2026-09-30 | |
| 🇸🇪 SE | Zolsketil pegylated liposomal 2 mg/ml Koncentrat till infusionsvätska, | Shortage | 2026-02-06 | 2026-08-31 | |
| 🇪🇸 ES | DOXORUBICINA ACCORD 2 MG/ML CONCENTRADO PARA SOLUCION PARA PERFUSION E | Shortage | 2025-12-17 | 2026-10-29 | Existen otros medicamentos con el mismo principio activo y m |
| 🇸🇪 SE | Doxorubicin Teva 2 mg/ml Injektionsvätska, lösning | Shortage | 2025-01-01 | 2026-12-31 | |
| 🇩🇪 DE | Doxorubicinhydrochlorid Bendalis 2 mg/ml | Shortage | 2024-11-15 | 2026-12-31 | Probleme in der Herstellung |
| 🇮🇪 IE | Doxorubicin Teva 2 mg / ml Concentrate for Solution for Infusion | Shortage | 2024-11-05 | — | Manufacturing delay |
| 🇩🇪 DE | DOXO-cell 150 mg Injektionslösung | Shortage | 2024-09-16 | 2027-01-19 | Probleme in der Herstellung |
| 🇩🇪 DE | DOXO-cell 50 mg Injektionslösung | Shortage | 2024-08-16 | 2027-01-19 | Probleme in der Herstellung |
Yes. As of 12 September 2026, availability issues are reported in: Germany, Spain, Ireland, Sweden. Availability is national — a shortage in one country does not mean it is short everywhere.
Agency prognoses on file range from 2026-09-30 to 2027-01-19. These are manufacturer-reported estimates and frequently move; check the linked register entry for the latest date.
8 of the active register entries indicate alternatives or equivalents (same active substance or an alternative treatment). Do not switch on your own — a pharmacist or prescriber can confirm the right substitute in your country.
Directly from the official medicines-agency registers that list Doxorubicin hydrochloride: BfArM (Germany), AEMPS CIMA (Spain), HPRA (Ireland), Läkemedelsverket (Sweden). Every row on this page links to the underlying official record, and the dataset is refreshed from the primary sources every morning. Cross-language matching groups the same active substance across registers, so national spellings all resolve to this page.
Pharmacies, patient sites and newsrooms are welcome to embed the live status of Doxorubicin hydrochloride — free, with attribution. Copy this snippet:
<iframe src="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/doxorubicin-hydrochloride/embed.html" width="100%" height="150" loading="lazy" style="border:1px solid #e1e0d9;border-radius:12px" title="Doxorubicin hydrochloride availability in Europe"></iframe> <p style="font-size:12px">Source: <a href="https://www.mobidoctor.eu/medicine-shortages/medicine-shortages/doxorubicin-hydrochloride/">Doxorubicin hydrochloride shortage status — European Medicine Shortage Tracker</a> by MobiDoctor</p>